linoleyl alcohol: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(9Z,12Z)-octadecadien-1-ol : A long chain fatty alcohol that is octadecanol containing two double bonds located at positions 9 and 12 (the 9Z,12Z-geoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5365682 |
| CHEBI ID | 73534 |
| SCHEMBL ID | 33878 |
| MeSH ID | M0165985 |
| Synonym |
|---|
| 9,12-octadecadien-1-ol, (z,z)- |
| AKOS015839888 |
| linoleyl alcohol |
| 506-43-4 |
| O0225 |
| cis,cis-9,12-octadecadien-1-ol |
| (9z,12z)-octadeca-9,12-dien-1-ol |
| unii-p4ox1289yw |
| einecs 208-038-1 |
| 9,12-octadecadien-1-ol, (9z,12z)- |
| p4ox1289yw , |
| (9z,12z)-octadeca-9,12-dien-1-ol;cis,cis-octadeca-9,12-dienol |
| A828219 |
| cis,cis-octadeca-9,12-dien-1-ol |
| cis,cis-octadeca-9,12-dienol |
| (z,z)-octadeca-9,12-dien-1-ol |
| 9-cis,12-cis-octadecadien-1-ol |
| CHEBI:73534 |
| (9z,12z)-octadecadien-1-ol |
| linoleyl alcohol [usp-rs] |
| BP-30113 |
| SCHEMBL33878 |
| (9z,12z)-9,12-octadecadien-1-ol # |
| (z,z)-9,12-octadecadien-1-ol |
| LMFA05000557 |
| CS-W005627 |
| mfcd00056667 |
| linoleyl alcohol, united states pharmacopeia (usp) reference standard |
| DS-5209 |
| DTXSID50881240 |
| 224948-75-8 |
| HY-W005627 |
| Class | Description |
|---|---|
| long-chain primary fatty alcohol | A long-chain fatty alcohol in which the hydroxy group is attached to a methylene (CH2) group. |
| fatty alcohol 18:2 | Any fatty alcohol containing 18 carbons and 2 double bonds. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||